Hims & Hers Cuts 2026 EBITDA Outlook, Q4 Guidance Far Below Consensus; Shares Down 18%
HIMS sits 37% above its 52-week low of $13.74 on elevated volume (4.1× avg).
Summary
Hims & Hers trimmed its full-year 2026 revenue outlook to $3.13-$3.15 billion from $3.1-$3.3 billion and cut adjusted EBITDA guidance to $257-$277 million from $275-$325 million. The fourth-quarter revenue guide of $875-$895 million sits well below the $953.45 million consensus, and the company flagged at least $20 million of deferred weight-loss membership revenue that slips into January. Q3 itself missed on both lines: a 14-cent loss per share versus an 8-cent profit expected, revenue of $890.4 million just shy of the $892.9 million consensus, and gross margin down about 7 points quarter-over-quarter to 57% as lower-margin branded weight-loss and international sales scale. Subscribers hit nearly 2.8 million, up 13% year-over-year, but fell by 100,000 net sequentially after the company pulled back marketing in domestic weight loss. Needham cut its price target to $32 from $42 but kept Buy, calling the reset a buying opportunity. Shares were down 18.2% at $18.76 Tuesday, extending the slide from Monday's report.
At the time of this announcement, HIMS was trading at $18.85 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $13.74 to $42.70. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Benzinga.